The importance of personalized medicine in urological cancers

Personalized medicine (PM) refers to a set of medical, diagnostic, and therapeutic activities and approaches based on the specific characteristics of each patient chr ('39')s genome. In fact, individual-centered medical approaches are based on personalization, meaning that each person chr ('39')s gene sequence and polymorphisms (SNPs) are different and explain the different courses of urological cancers and the different efficiencies of individuals in a protocol. The treatment is constant. Based on data from the Human Genome and Gene Sequence Project, along with proteomics, metabolomics, and transcriptomics information, a number of molecular biomarkers are suggested as potential targets for guided cancer therapies. In urological malignancies, the expression and clinical significance of carbonic anhydrase in type IX in the bladder, kidney, and urinary tract cancers and the primary therapeutic approaches have been discussed. Prostate membrane antigen and radiolabeled analog neuropeptide receptors for prostate cancer are considered valuable prognostic factors in clinical trials. The results of the treatment of patients with urological cancers from a person-centered medical perspective will impose a lower cost on the patient and more effective treatment, which we will discuss in this article